Alphatec starts clinical trial of OsseoFix
This article was originally published in Clinica
Executive Summary
Spine disorder specialist Alphatec has started a clinical trial of its OsseoFix spinal fracture reduction system. The German study, in 30 patients with vertebral compression, will evaluate the level of pain relief and vertebral stability seen with the device. The Carlsbad, California company filed OsseoFix with the US FDA last month, and hopes to receive 510(k) clearance and launch it by late 2008. OsseoFix uses less cement during a surgical procedure and reduces fractures compared with other common procedures, kyphoplasty and vertebroplasty, Alphatec says. The former involves inflating a balloon catheter in the damaged vertebrae and reinforcing the space with bone cement; while the latter directly injects cement under high pressure. According to Alphatec OsseoFix could reduce the risk of cement extravasation and reduce surgical complications.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.